Replies to post #387048 on NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

I don't know where it is on the 10k or annual report but Linda said they were doing it at the ASM.
Here is the verbatim quote from Ike transcript:

Once we have the initial license, then we expect to begin producing vaccine products for our existing programs as we've been doing at the small facility in London that we've been using up 'til now.

I have no reason to believe she would lie or mislead us.
I suggest you discuss this with Dave Innes and see if he can shed some light on how the are accounting for the revenue and expense associated with the program if they are not showing up where you would expect the to be.
good luck

[MasterKit]

From the 10k:

Revenue Recognition

The Company recognizes revenue in accordance with the terms stipulated under the patient service contract. In various situations, the Company receives certain payments for DCVax®-L for patient treatment. These payments are assessed and recognized in accordance with ASC 606 in the period when the performance obligation has been met.

Not sure where it shows up in the balance sheets, but not sure how else they could realize revenues in "research and other".

[exwannabe]

Jerry, have to disagree with you here.

The costs associated with manufacturing of a drug that is still in development are catagorized as R&D. I can certainly see a solid argument that the costs of "Specials" manufacturing should go to COGS, but this is an edge case so not going to war on the issue.

The revenue line that has been reported for several years is consistent with what we would expect from Specials. We know the program has a capacity for 4-6 patients/month. Logistics would preclude it actually producing that much though (you can not freely schedule the patients). The revenue had been slowly growing from about to about $700K/q in Q4 '19. Discounts always exist in this field, and 10 patients/Q at $70k each looks reasonable.

Then the revenue fell to 0 in Q2 '20 with Covid, and has now slowly grown back to less than half the previous levels. That all looks to be a reasonable pattern.

If this is the revenue from Specials, then they are not manufacturing capacity limited as of today. So do not see why anybody expects some huge increase due to Sawston this year.